logo-loader
viewiOmx Therapeutics AG

iOmx Therapeutics compounds show 'great promise' to be clinically developable

iOmx Therapeutics AG CEO Apollon Papadimitriou spoke to Proactive at the Biotech Showcase 2020 in San Francisco. The Germany-based biopharmaceutical company is advancing a preclinical stage pipeline of drug candidates that have the potential to address immunotherapy-resistant cancers.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Xpediator’s 'solid pandemic plan' to see company much stronger on other side

Xpediator (LON:XPD) chief financial officer Robert Ross joins Steve Darling from Proactive ahead of its AGM. Ross talks about its pandemic management plan, its pipeline of acquisition opportunities and how financially secure the company is.

47 minutes ago

2 min read